ATE301654T1 - Naphthyridinderivate - Google Patents

Naphthyridinderivate

Info

Publication number
ATE301654T1
ATE301654T1 AT02702326T AT02702326T ATE301654T1 AT E301654 T1 ATE301654 T1 AT E301654T1 AT 02702326 T AT02702326 T AT 02702326T AT 02702326 T AT02702326 T AT 02702326T AT E301654 T1 ATE301654 T1 AT E301654T1
Authority
AT
Austria
Prior art keywords
custom
character
tif
therapy
naphthyridine derivatives
Prior art date
Application number
AT02702326T
Other languages
English (en)
Inventor
Francoise J Gellibert
Charles D Hartley
Neil Mathews
James M Woolven
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE301654T1 publication Critical patent/ATE301654T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02702326T 2001-02-02 2002-01-30 Naphthyridinderivate ATE301654T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0102672.3A GB0102672D0 (en) 2001-02-02 2001-02-02 Compounds
PCT/EP2002/000939 WO2002062794A2 (en) 2001-02-02 2002-01-30 Compounds

Publications (1)

Publication Number Publication Date
ATE301654T1 true ATE301654T1 (de) 2005-08-15

Family

ID=9908018

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02702326T ATE301654T1 (de) 2001-02-02 2002-01-30 Naphthyridinderivate

Country Status (7)

Country Link
US (1) US20040063949A1 (de)
EP (1) EP1358187B1 (de)
JP (1) JP2004523541A (de)
AT (1) ATE301654T1 (de)
DE (1) DE60205455T2 (de)
GB (1) GB0102672D0 (de)
WO (1) WO2002062794A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AU2003256783A1 (en) * 2002-07-25 2004-02-16 Scios, Inc. METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
EP1543001B1 (de) 2002-09-17 2007-08-15 Eli Lilly And Company Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
OA12929A (en) * 2002-09-18 2006-10-13 Pfizer Prod Inc Pyrazole derivatives as transforming growth (TGF) inhibitors.
KR20050057392A (ko) 2002-09-18 2005-06-16 화이자 프로덕츠 인크. 전환성장인자(ｔｇｆ) 억제제로서의 신규한 이미다졸 화합물
MXPA05002332A (es) 2002-09-18 2005-06-08 Pfizer Prod Inc Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
OA12925A (en) * 2002-09-18 2006-10-13 Pfizer Prod Inc Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors.
OA12927A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Novel triazole and oxazole compounds as transforming growth factor (TGF) inhibitors.
WO2004048381A2 (en) * 2002-11-22 2004-06-10 Eli Lilly And Company Pyrazoloazepine compounds as pharmaceutical agents
EP1567527A1 (de) 2002-11-27 2005-08-31 Eli Lilly And Company Kondensierte pyrazolderivate
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
EP2918288B1 (de) 2006-10-03 2017-08-16 Genzyme Corporation Verwendung von TGF-beta-Antagonisten zur Behandlung von Kleinkindern mit dem Risiko der Entwicklung von bronchopulmonaler Dysplasie
KR20090066297A (ko) * 2006-10-16 2009-06-23 화이자 프로덕츠 인크. 치료용 피라졸릴 티에노피리딘
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
BR112014009789A2 (pt) 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
EP3313420B1 (de) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Verfahren und zusammensetzungen in bezug auf hämatopoetische stammzellenexpansion, -anreicherung und -pflege
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US10760057B2 (en) 2017-07-06 2020-09-01 Wisconsin Alumni Research Foundation Human pluripotent stem cell-based screening for smooth muscle cell differentiation and disease
JP7653257B2 (ja) * 2018-03-23 2025-03-28 サイトー 骨格筋肥大誘発剤としてのａｌｋ５阻害剤
AU2019396360A1 (en) 2018-12-11 2021-05-27 Theravance Biopharma R&D Ip, Llc Naphthyridine and quinoline derivatives useful as ALK5 inhibitors
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
IL293084A (en) * 2019-11-22 2022-07-01 Theravance Biopharma R& D Ip Llc Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541253A (ja) * 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
KR20010114267A (ko) * 1999-05-14 2001-12-31 오르토-맥네일 파마슈티칼, 인코퍼레이티드 치환된 3-피리딜-4-아릴피롤과 관련 치료방법 및 예방방법

Also Published As

Publication number Publication date
EP1358187A2 (de) 2003-11-05
JP2004523541A (ja) 2004-08-05
WO2002062794A2 (en) 2002-08-15
WO2002062794A3 (en) 2002-10-03
DE60205455T2 (de) 2006-06-14
EP1358187B1 (de) 2005-08-10
GB0102672D0 (en) 2001-03-21
DE60205455D1 (de) 2005-09-15
US20040063949A1 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
DE60205455D1 (de) Naphthyridinderivate
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
DE602004011394D1 (en) Thiazolderivate
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
SE9902987D0 (sv) Novel compounds
ATE248837T1 (de) Chinuclidin-acrylamide
PL367682A1 (en) Dolastatin 10 derivatives
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
PL367814A1 (en) 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
CA2498047A1 (en) Novel imidazole compounds as transforming growth factor (tgf) inhibitors
GB0112348D0 (en) Compounds
WO2004026306A3 (en) Pyrazole derivatives as transforming growth factor (tgf) inhibitors
SE9903997D0 (sv) New compounds
ATE233754T1 (de) Diphenyl-piperidin derivate
SE0302756D0 (sv) Novel Compounds
SE0102440D0 (sv) New compound
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
MXPA04005809A (es) Inhibidores de proteinas quinasas.
SE0102641D0 (sv) Novel compounds
AU2003245989A1 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
SE0102639D0 (sv) Novel compounds
SE0303075D0 (sv) 4-substituted imidazoles
SE9901530D0 (sv) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties